Introduction
Radical cystectomy is the standard of care for localized muscle-invasive bladder cancer (MIBC). To date, the use of laparoscopic or robotic surgery is still under debate for patients with MIBC. Specifically, robotic surgery represent a surgical option according to National Comprehensive Cancer Network (NCCN) guidelines. However, the European Association of Urology (EAU) guidelines rank robotic radical cystectomy (RARC) as investigational procedure [1] . This recommendation is based on absence of data indicating an advantage of RARC over open radical cystectomy (ORC) [2] [3] . In randomized controlled trials (RCTs) no differences in length of stay (LOS), in hospital mortality, intraoperative and in hospital complications were identified between ORC and RARC . However, RARC patients had lower transfusions rates. It is noteworthy that only one of three RCT was adequately powered to compare RARC to ORC. [4] [5] [6] Based on these considerations, we re-examined [7] the effect of RARC on in-hospital morbidity and mortality as well as its impact on LOS and total hospital charges (THCGs).
Materials and methods

Data source
To assess complications and in hospital mortality rates of RARC vs ORC we relied on the National Inpatient Sample (NIS) database (2008) (2009) (2010) (2011) (2012) (2013) . The NIS is a set of longitudinal hospital inpatient databases included in the Healthcare Cost and Utilization Project family, created by the Agency for Healthcare Research and Quality through a Federal-state partnership [8] . The database includes 20% of United States inpatient hospitalizations, with discharge abstracts from 8 million hospital stays. It incorporates patient and hospital information, including Medicare, Medicaid, private insurance, and other insurance type patients.
Study population
Within the NIS database (2008-2013), we focused on patients with a primary diagnosis of bladder cancer (ICD-9-CM code 188; 233.7) aged ≥18 years. Patients with a secondary diagnosis of metastatic disease were excluded (ICD-9-CM code 197.x and 198.x).
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Primary procedure codes were used to identify radical cystectomy (ICD-9-CM code 57.7; 57.71; 57.79) patients. Secondary procedure codes were used to identify lymph node dissection (ICD-9-CM code 40.3; 40.5). Use of ileal conduit or continent (orthotopic neobladder or continent cutaneous reservoir) urinary diversion were identified using ICD-9 codes 56.51 or 57.87. Robotic procedures were identified according to the modifier codes 17.4 and 17.42 [7] .
Outcomes of interest
Complications rates were defined using secondary ICD-9 diagnostic codes, as previously described [9] [10] [11] . Intraoperative complications consisted of accidental blood vessel and/or nerve and/or organ puncture or laceration during the procedure.
Postoperative complications consisted of cardiac, respiratory, vascular, operative wound, genitourinary, transfusion, parenteral nutrition, miscellaneous medical and miscellaneous surgical [7] . LOS, provided by the NIS, is calculated by subtracting the admission date from the discharge date. Inflation-adjusted THCGs were defined according to NIS information [12] . In-hospital mortality information is coded from the disposition of the patient.
Patient and hospital characteristics
Patient age, gender, race/ethnicity (Caucasian, African American and Others), Charlson comorbidity index (CCI) [13] [14] and insurance status (private insurance, Medicare, Medicaid, and other [self-pay]) were defined according NIS information.
Additional risk variables consisted of hospital region (Northeast, Midwest, South, West) [15] , hospital size (small, medium and large) and hospital teaching vs. non-teaching status. Teaching institutions had an American Medical Association-approved residency program, were a member of the Council of Teaching Hospitals, or had a ratio of 0.25 or higher of full-time equivalent interns and residents to non-nursing home beds. [8] Lastly, annual hospital volume (low, medium and high), representing the number of performed at each participating institution during each study calendar year was calculated and stratified according to tertiles.
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Statistical analysis
First, medians and interquartile ranges, as well as frequencies and proportions were reported for continuous (age, LOS and THCGs) and categorical variables (gender, race, insurance status, CCI, annual hospital volume, region, hospital size, teaching status, lymph node dissection, parenteral nutrition, ileal conduit or continent urinary diversion and complications), respectively. The statistical significance of differences in medians and proportions was evaluated with the Kruskal-Wallis and chi-square tests.
Second, estimated annual percentage change (EAPC), was generated using the loglinear regression methodology. Third, nine separate sets of multivariable logistic regressions (MLRs) tested complications and in-hospital mortality rates after ORC and RARC. Fourth, multivariable Poisson regressions (MPR) models compared LOS after ORC and RARC. Fifth, log-linear regression compared THCGs after ORC and RARC. Sixth, the analyses where repeated after inverse probability of treatment weighting (IPTW) adjustment and clustering [16] .
All statistical tests were two-sided. The level of significance was set at p<0.05.
Analyses were performed using the R software environment for statistical computing and graphics (version 3.4.1; http://www.r-project.org/). represented an independent predictor for shorter LOS. After either RARC or ORC, the strongest determinants of higher LOS were wound complications (RR: 1.85, p<0.001), miscellaneous medical complications (RR: 1.4, p<0.001) and respiratory complications (RR:
Results
Descriptive characteristics, rates of cystectomy and total hospital charges over time
1.27, p<0.001). (Table 5 )
Multivariable log-linear regression models testing for impact of surgical technique on total hospital charges adjusted for clustering and IPTW
In multivariable log-linear regression models adjusted for all covariates, RARC (OR:
1.09, p=0.005) represented an independent predictor for higher THCGs. After either RARC or ORC the strongest determinants of higher THCGs were wound complications (OR:1.48; p<0.001), miscellaneous surgical complications (OR: 1.33, p<0.001) and respiratory complications (OR: 1.26, p<0.001). (Table 6) 
Discussion
Robotic surgery is nowadays widely adopted in urological surgery. However, its role in radical cystectomy for MIBC is still under debate. Data from RCTs are in disagreement [4] [5] [6] . Institutional series were published comparing ORC and RARC.
However, the sample sizes were small and usually, originated from tertiary care referral centers [17] [18] [19] .
The most recent population based study focused on NIS database was published by Yu et al. [7] and ORC rates decreased from 97.5 to 78.8% (Figure 1 ). This increase is higher than reported by Hu et al. [20] and can be explained by greater contemporary nature of our data that include patients operated in 2013. These findings also confirm the confidence in RARC based on an ongoing increase in annual RARC rates.
Second, average THCGs difference between RARC and ORC was 10 028 US dollars in 2008. However, a significant decrease of THCGs was recorded after RARC (EAPC: -6.8%, CI: -9.6 to -3.9; p=0.01). Conversely, decreasing in THCGs in ORC was not statistically significant (EAPC: -2.8%, CI: -5.1 to -0.5; p=0.08). However, ORC represents the standard of care. In consequence, little changes in THCGs were expected during the span of the study,
given that relative few modifications have been made to the surgical technique and perioperative care in ORC. It is noteworthy that overtime the decreasing average THCGs for RARC reduced the difference between RARC and ORC from an initial gap of 10 028 USD to 891 USD. To the best of our knowledge we are the first to provide a detailed charge analyses that is based on annual figures (Figure 2 ) in additional to annual trends. Other investigators reported THCGs comparison that relied on analyses on figures recorded for one single year of observation [7] or cumulative figures over several years [22] , neither allowed to arrive at the observation reported in the current study where a decreasing gap was observed between RARC and ORC. This finding is particular important in the context of cost containment for health expenditures. This said, when the entire patient cohort is considered over the entire study span RARC remains more expensive relative to ORC (OR:
1.09, p<0.001) ( Table 6 ).
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Third, in MLR models predicting complications, RARC resulted in lower overall, respiratory, wound, genitourinary and miscellaneous surgical complications. Moreover, patients underwent RARC had lower transfusions and parenteral nutrition rates. The results were confirmed after IPTW and adjustment for clustering (Table 4) . Our results showed several differences from the previous report of Yu et al. [7] , who found no difference between ORC and RARC in transfusion, respiratory, wound, genitourinary and miscellaneous surgical complications rates. Conversely, the authors reported lower inhospital mortality in RARC patients, this finding was not confirmed in our analyses. Taken together, our findings are equally encouraging to those reported for THCGs with an advantage shown for RARC over ORC.
Fourth, in MPR models predicting LOS after RARC and ORC, RARC resulted as a predictor of shorter LOS (OR: 0.91, p<0.001) ( Table 5) . Our results are in disagreement with Yu et al. [7] who reported no difference between RARC and ORC after propensity score matching. However, our results are consistent with Leow et al. [22] , Hu et al. [20] and Hanna et al. [21] . Taken together, these observations show an advantage on LOS for RARC in more contemporary patients.
In summary, we examined several different endpoints and RARC demonstrated better outcomes for postoperative complications and LOS. However, RARC still showed a THCGs disadvantage. Moreover, analyses overtime showed improvement in RARC characteristic. For example, THCGs decreased overtime. Based on this observation RARC represent a valid alternative to ORC in properly select patients in whom RARC can be delivered at tertiary care institutions by experienced surgeons.
Our study is not devoid of limitations. First, only inpatients information were available in the database we analyzed and no data were available regarding readmissions and late complications [7] . Second, our study was unable to adjust for tumor characteristics. Third, we were not able to control for some risk factors, such as laboratory values, opioid use and anesthesia-specific considerations.
Fourth, in our analyses was not possible to distinguish between intra-corporeal and extracorporeal urinary diversion in RARC patients because of the lack of a specific modifier This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
code. Finally, we were also not able to assess whether chemotherapy or radiation therapy was given prior to surgery.
Conclusion
RARC is related to lower in-hospital rates of overall complications and transfusions.
In consequence, RARC is a safe and feasible technique in select muscle invasive bladder cancer patients. Moreover, RARC is associated with shorter LOS albeit, higher THCGs.
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Figure 2
Annual average cost trend according to open and robotic cystectomy
